Hericium erinaceus extract as well as main components and application thereof

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of a medicinal and edible traditional Chinese medicinal material Hericium erinaceum extract as a medicine or a functional product for relieving a pulmonary fibrosis process. The hericium erinaceus extract is prepared by the following steps: carrying out heating reflux extraction on freeze-dried powder of a traditional Chinese medicinal material hericium erinaceus sporocarp with a 70% ethanol solution, collecting an extracting solution, carrying out vacuum concentration, carrying out macroporous resin column chromatography, and eluting the part with 70% ethanol to obtain the hericium erinaceus extract (the yield is 8%). The hericium erinaceus extract obtained by the invention can improve weight loss of a lung fiber model and hydroxyproline content in lung tissue, and relieve pathological characteristics such as lung tissue inflammatory cell infiltration, alveolar atrophy and collapse, alveolar wall thickening and collagen deposition, so that the degree of pulmonary fibrosis is obviously relieved. The medicine or functional food prepared from the hericium erinaceus extract has the advantages of definite curative effect and high safety.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicine, and specifically relates to an application of Hericium erinaceus extract in treating pulmonary fibrosis. Background Art

[0002] Pulmonary fibrosis (PF) is a chronic, progressive and difficult-to-cure lung disease characterized by excessive deposition of extracellular matrix (ECM) and lung structural remodeling. [1] Its pathological characteristics include chronic inflammation, activation of myofibroblasts, and excessive deposition of ECM, which ultimately lead to fibrosis and scarring of lung tissue, causing serious impact on respiratory function. [2] . Common symptoms include dry cough, fatigue, chest discomfort and weight loss. As the disease progresses, some patients may also experience difficulty breathing, and even lead to respiratory failure and death. The cause of most pulmonary fibrosis is unknown, which is called idiopathic interstitial pneumonia, a large type of interstitial lung disease. Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic interstitial lung disease that is difficult to cure. Its onset is closely related to many factors such as age, environmental exposure, viral infection, etc. It has common interstitial pneumonia manifestations in histology, and the clinical manifestations are mostly cough and progressive dyspnea symptoms. [3] The typical characteristics of IPF are remodeling of the interstitium, trachea and alveoli, accompanied by abnormal inflammatory response, excessive deposition of extracellular matrix (ECM) and decreased lung function. [4] IPF mostly occurs in middle-aged and elderly people, and the incidence rate is increasing every year. The progression of IPF patients from diagnosis to end-stage respiratory impairment and even death is only 2 to 5 years. [5] So far, anti-PF drugs approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), such as pirfenidone and nintedanib, can only be used as palliative treatments for PF and are accompanied by serious adverse reactions, bringing huge economic and living burdens to patients. [6] Traditional Chinese medicine has long-term clinical experience in treating idiopathic pulmonary fibrosis, with good efficacy and few adverse reactions.

[0003] Hericium erinaceus, also known as Hericium erinaceus, Monkey mushroom, etc., is a higher fungus belonging to the Basidiomycetes, Agaricus, Russulares, Hericium family. [7] Hericium erinaceus is mild in nature and sweet in taste. It has the function of "aiding digestion and benefiting the five internal organs". As a precious medicinal and edible mushroom, it has a history of more than 2,000 years in my country and other Asian countries. In addition to polysaccharides, amino acids and inorganic elements, it also contains a variety of biologically active substances such as polypeptides, terpenes, sterols, polyphenols and adenosine. [7]Hericium erinaceus is not only nutritious, but also has good medicinal value, such as anti-ulcer, anti-inflammatory, immunity enhancement, anti-tumor, hypoglycemic, gastric protection and intestinal health promotion, so Hericium erinaceus is an important resource for the development of drugs and functional foods. [8] .

[0004] However, to date, there are no reports that Hericium erinaceus extract can alleviate pulmonary fibrosis.

[0005] References:

[0006] 1.Noble, PW, CEBarkauskas, and D.Jiang, Pulmonaryfibrosis: patterns and perpetrators. The Journal of clinical investigation, 2012.122(8):p.2756-2762.

[0007] 2. Wynn, TA, Integrating mechanisms of pulmonary fibrosis. Journal of Experimental Medicine, 2011.208(7):p.1339-1350.

[0008] 3. King, TE, A. Pardo, and M. Selman, Idiopathic pulmonary fibrosis. The Lancet, 2011.378(9807): p.1949-1961.

[0009] 4. Gross, TJ and GWHunninghake, Idiopathic pulmonary fibrosis. New England Journal of Medicine, 2001.345(7): p.517-525.

[0010] 5.Richeldi, L., HR Collard, and MG Jones, Idiopathic pulmonary fibrosis. The Lancet, 2017.389(10082):p.1941-1952.

[0011] 6. Lederer, DJ and FJ Martinez, Idiopathic pulmonary fibrosis. New England Journal of Medicine, 2018.378(19):p.1811-1823.

[0012] 7.Thongbai,B.,et al.,Hericium erinaceus,an amazing medicinal mushroom.Mycological Progress,2015.14:p.1-23.

[0013] 8. Friedman, M., Chemistry, nutrition, and health-promoting properties of Hericium erinaceus (Lion's Mane) mushroomfruiting bodies and mycelia and their bioactive compounds. Journal of agricultural and food chemistry, 2015.63(32): p.7108-7123. Summary of the invention

[0014] Purpose of the Invention

[0015] The present invention provides a Chinese medicinal material Hericium erinaceus extract which is both a medicine and an food and can alleviate the process of pulmonary tissue fibrosis, as well as a preparation method and application thereof. The Hericium erinaceus extract of the present invention has the effect of alleviating pulmonary fibrosis, and the Hericium erinaceus extract used is derived from artificially cultivated Hericium erinaceus, has the characteristics of stable and safe source, significant effect, etc., and is worthy of wide promotion.

[0016] The invention discloses an extract of Hericium erinaceus, a Chinese medicinal material having both medicinal and edible properties, in particular to an ethanol extract of Hericium erinaceus.

[0017] The invention discloses an application of a Hericium erinaceus extract in preparing a medicine or a functional product for treating pulmonary fibrosis.

[0018] The application is characterized in that the Hericium erinaceus extract is prepared by the following steps: taking 1.25 kg of Hericium erinaceus fruiting bodies, crushing them, heating and refluxing them with a 70% ethanol solution, collecting the extract, concentrating it under reduced pressure, and eluting it with 70% ethanol through a macroporous resin column chromatography to obtain the Hericium erinaceus extract.

[0019] The Hericium erinaceus extract mainly contains agamidazole C, agamidazole D, agamidazole A and agamidazole C.

[0020]

[0021] The dosage form of the medicine or functional product is granules, tablets, pills, drops, injections, capsules, powders or decoctions.

[0022] Further: the administration routes of the drug or functional product include oral drugs, injectable drugs, implantable drugs, external drugs, sprays, inhaled drugs or combinations of the foregoing drugs; the dosage form of the drug or functional product can be any one of tablets, capsules, pills, suppositories, aerosols, oral liquid preparations, granules, powders, injections, syrups, wine preparations, tinctures, lotions or films, etc.; the treatment includes relief.

[0023] Beneficial Effects

[0024] The present invention is proved by the results of in vivo pharmacological experiments that Hericium erinaceus extract can improve bleomycin-induced pulmonary fibrosis in mice: a bleomycin-induced pulmonary fibrosis model in mice was induced by instillation of tracheal administration once, and Hericium erinaceus extract was continuously administered by gavage for 14 days starting from the 8th day after modeling. The weight change and survival rate of mice were observed, and the changes in lung tissue pathological sections were observed by HE and Masson staining, including pulmonary inflammatory cell infiltration, alveolar atrophy and collapse, alveolar wall thickening and collagen deposition, etc., to comprehensively evaluate the pharmacological mechanism of Hericium erinaceus extract in reducing pulmonary fibrosis in model mice. The results showed that compared with the bleomycin model group, the lung coefficient of mice in each Hericium erinaceus administration group was reduced, indicating that the pulmonary fibrosis and collagen fiber deposition of mice in the Hericium erinaceus administration group were improved. Compared with the bleomycin model group, the lung condition of mice in the Hericium erinaceus administration group was improved. In the Hericium erinaceus low-dose group, inflammatory cell infiltration was seen in part of the lung interstitium, and the alveolar septum was thickened, accompanied by alveolar wall destruction. In the high-dose group of Hericium erinaceus, there was no infiltration of inflammatory cells in the lung interstitium and thickening of the alveolar septa. Some alveolar septa became thinner, alveolar atrophy and collapse were rare, marginal alveoli were intact, and the alveolar structure was restored. Compared with the bleomycin model group, the lung conditions of mice in the Hericium erinaceus group were improved, but there was no toxicity and side effects of bleomycin. Some collagen fiber immersion was still observed in the low-dose group of Hericium erinaceus. After 14 days of intervention with the high-dose group of Hericium erinaceus and nintedanib, the collagen fibers in the mouse lung interstitium were significantly reduced, and there was no significant difference between the high-dose group of Hericium erinaceus and the nintedanib group, and there was no toxicity and side effects of nintedanib.

[0025] Further, the Hericium erinaceus extract of the present invention mainly contains 4 components, which are determined to be agamidinone C, agamidinone D, agamidin A and agamidin C by liquid column chromatography separation and standard sample comparison analysis. These four components and Hericium erinaceus precursor can significantly inhibit the transdifferentiation of lung fibroblasts and the secretion of collagen α-SMA and Cold1 caused by growth factor TGFβ1 in vitro, indicating that agamidinone C, agamidinone D, agamidin A and agamidin C in Hericium erinaceus extract have certain anti-pulmonary fibrosis effects, and the above compounds play a synergistic role. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. The drawings in the following description are only some embodiments of the present invention.

[0027] Figure 1 Survival rate curves of mice in each group in the example.

[0028] Figure 2 Body weight changes of mice in each group in the examples.

[0029] Figure 3 The final body weight of each group of mice in the examples.

[0030] Figure 4 The lung coefficient and body weight of each group of mice in the example.

[0031] Figure 5 The degree of inflammation in the lung tissue of each group of mice in the example (H&E staining) (×200, scale bar = 50 μm).

[0032] Figure 6 Lung histopathological inflammation scores of mice in each group in the example. CON blank; MOD model; NDN nintedanib; HTG Hericium erinaceus extract. Compared with the blank group, *p<0.05, **p<0.01, ***p<0.001. Compared with the model group, #p<0.05, ##p<0.01, ###p<0.001.

[0033] Figure 7 The degree of fibrosis in the lung tissue of each group of mice in the example (Masson staining) (×200, scale bar=50 μm).

[0034] Figure 8Pathological fibrosis scores of the lung tissues of mice in each group in the embodiment; CON blank; MOD model; NDN nintedanib; HTG Hericium erinaceus extract. Compared with the blank group, *p<0.05, **p<0.01, ***p<0.001. Compared with the model group, #p<0.05, ##p<0.01, ###p<0.001.

[0035] Fig. 9 E-cadherin, α-SMA, Vimentin and GAPDH gene expression in lung tissues of mice in each group in the example. CON blank; MOD model; NDN nintedanib; HTG Hericium erinaceus extract. Compared with the blank group, *p<0.05, **p<0.01, ***p<0.001. Compared with the model group, #p<0.05, ##p<0.01, ###p<0.001.

[0036] Fig.10 Effects of ginsenoside C, ginsenoside D, ginsenoside A and ginsenoside C on the proliferation of primary mouse lung fibroblasts. Compared with the blank group, ***p<0.001. Compared with the TGF-β1 intervention group, #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001. DETAILED DESCRIPTION

[0037] The experimental methods in the following examples of the present invention without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturers. The various commonly used chemical reagents used in the examples are all commercially available products.

[0038] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The following is an explanation in conjunction with specific embodiments.

[0039] Example 1: A method for preparing Hericium erinaceus extract and observation of its anti-pulmonary fibrosis effect, comprising the following steps:

[0040] 1) Preparation of Hericium erinaceus extract:

[0041] Take 1.25 kg of Hericium erinaceus fruiting bodies, crush them, extract them with 70% ethanol solution by heating and refluxing, collect the extract, concentrate it under reduced pressure, and perform macroporous resin column chromatography. The Hericium erinaceus extract is obtained from the 70% ethanol elution part with a yield of 8%.

[0042] 2) Establishment of pulmonary fibrosis model:

[0043] One hundred 8-week-old adult male C57BL / 6 mice (23-25 ​​g) (purchased from Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd., Jiangsu, China, animal license SYXK (#) 2023-0019) were randomly divided into 5 groups. The mice were housed in clean cages under stable room temperature (22 ° C) and lighting conditions (12-hour light / dark cycle), and free access to food and water was allowed. After one week of adaptive feeding, the mice were randomly divided into five groups: blank control group (Control, C), bleomycin model group (Model, M), low-dose Hericium erinaceus group (HTG-L, 25 mg / kg), medium-dose Hericium erinaceus group (HTG-H, 50 mg / kg), and positive drug nintedanib group (NDN, 40 mg / kg). After fasting for 12 hours before modeling, the mice were intratracheally injected with bleomycin (3.5 mg / kg, 0.9% sterile saline) or 0.9% sterile saline (control). Seven days after bleomycin modeling, the low-dose Hericium erinaceus group (25 mg / kg), the high-dose Hericium erinaceus group (50 mg / kg), and the nintedanib group (40 mg / kg) were intragastrically administered once a day for 14 days, while the control group and the model group received the same amount of solvent. The body weight and survival status of the mice were recorded every day.

[0044] 3) Experimental results analysis:

[0045] Compared with the blank control group, mice in the bleomycin model group began to die from the 12th day. As of the 21st day after modeling, the survival rate of mice in the bleomycin model group was only 65%. The mortality rate of mice treated with Hericium erinaceus extract was significantly lower than that of the bleomycin model group. Among them, the low-dose Hericium erinaceus group began to die from the 13th day, and the mortality rate of mice was lower than that of the bleomycin model group; the high-dose Hericium erinaceus group began to die from the 14th day, and the mortality rate of mice was lower than that of the bleomycin model group. The degree of impact on mouse mortality is higher than that of low doses (such as Figure 1 (shown)

[0046] From the 4th day on, the weight gain of mice in the bleomycin model group showed a significantly slower trend than that of the blank control group. Compared with the bleomycin model group, the weight loss of mice treated with Hericium erinaceus extract was improved. Among them, the weight gain of the Hericium erinaceus extract treatment group and the nintedanib treatment group was significantly higher than that of the bleomycin model group from the 2nd week; the effect of low-dose Hericium erinaceus extract on the improvement of mouse weight was not much different ( Figure 2 ).

[0047] The final body weight of mice in the pulmonary fibrosis model group was significantly lower than that in the Hericium erinaceus extract treatment group ( Figure 3), Hericium erinaceus extract at high and low doses can significantly improve the weight loss rate of mice. In addition, the final body weight of mice in the Hericium erinaceus extract group was similar to that of the positive drug nintedanib treatment group, with no statistical difference. In summary, it can be seen that Hericium erinaceus extract has a significant improvement effect on the body weight and survival rate of mice with bleomycin-induced pulmonary fibrosis.

[0048] Example 2: Collection and analysis of lung tissue samples from each group before and after treatment with Hericium erinaceus extract

[0049] On the 22nd day after administration of bleomycin, the mice were anesthetized with 0.3% sodium pentobarbital, and blood and lung tissue were collected from the mice. Lung tissue samples were fixed in 4% paraformaldehyde solution for at least 24 hours, then dehydrated, transparent, and paraffin-embedded. After cutting into 4-7 μm thick sections, hematoxylin-eosin (H&E) and Masson trichrome staining were performed. Representative images were obtained using a digital pathology section scanning system (purchased from GPBio, Shanghai, China). All data are expressed as mean ± SD (x ± s). GraphPad Prism 8 statistical software was used for processing, and one-way ANOVA was used for statistics. P < 0.05 indicated that the difference was statistically significant.

[0050] like Figure 4 As shown in the figure, compared with the blank control group, as the modeling time went on, the lung coefficient of mice was significantly higher than that of the blank control group, indicating that the pulmonary fibrosis and collagen fiber deposition of mice in the bleomycin model group were more serious. Compared with the bleomycin model group, the lung coefficient of mice in each Hericium erinaceus administration group was reduced, indicating that the pulmonary fibrosis and collagen fiber deposition of mice in the Hericium erinaceus administration group were improved.

[0051] like Figure 5 and Figure 6 As shown in the figure, compared with the blank control group, after 21 days of bleomycin intervention, the smooth muscle of the mice lungs was significantly damaged, the inflammatory cell infiltration broke through the basement membrane, a large number of inflammatory cells infiltrated in the lung interstitium, and the alveolar wall proliferated and destroyed. Compared with the bleomycin model group, the lung conditions of the mice in the Hericium erinaceus administration group improved. In the low-dose Hericium erinaceus group, inflammatory cell infiltration was observed in some lung interstitium, the alveolar septum thickened, and the alveolar wall was destroyed. In the high-dose Hericium erinaceus group, no inflammatory cell infiltration in the lung interstitium and thickening of the alveolar septum were observed, some alveolar septa were thinned, alveolar atrophy and collapse were rare, the marginal alveoli were intact, and the alveolar structure was restored.

[0052] like Figure 7 and Figure 8As shown in the figure, compared with the blank control group, after 21 days of bleomycin intervention, accompanied by destruction of alveolar structure, obvious collagen fiber infiltration was observed in the lung interstitium. Compared with the bleomycin model group, the lung condition of mice in the Hericium erinaceus administration group was improved. Some collagen fiber infiltration was still observed in the low-dose Hericium erinaceus group. After 14 days of intervention with the high-dose Hericium erinaceus group and nintedanib, the collagen fibers in the mouse lung interstitium were significantly reduced, and no significant difference was observed between the high-dose Hericium erinaceus group and the nintedanib group.

[0053] Example 3: Changes in mRNA levels of E-cadherin, α-SMA and Vimentin proteins in lung tissues of each group before and after treatment with Hericium erinaceus extracts Total RNA was extracted using an RNA extraction kit (purchased from TianGen, Beijing, China). After measuring RNA concentration using a Nanodrop One micro-spectrophotometer, HiScriptIIQRT SuperMix reagent (purchased from Vazyme, Nanjing, China) was added to all RNA samples (quantitative 1000 ng) for reverse transcription. The reversed samples were cyclically amplified in a RocheLightCycler480 (purchased from Roche, Basel, Switzerland) instrument using ChamQSYBR qPCR Master Mix (purchased from Vazyme, Nanjing, China), using GAPDH as an internal reference gene. The PCR conditions were: 95°C for 30 seconds for enzyme activation, 95°C for 10 seconds, and 60°C for 30 seconds for 40 cycles for amplification, and the data were processed using the 2-ΔΔct calculation method (purchased from Sangon Biotech Shanghai, China). RT-PCR was used to detect the mRNA expressions of E-cadherin, α-SMA and Vimentin proteins in the lung tissues of mice in each group.

[0054] like Fig. 9 As shown in the figure, compared with the blank control group, the expression of E-cadherin in the lung tissue of mice in the bleomycin model group was significantly reduced, and α-SMA and Vimentin were significantly increased, indicating that bleomycin induced the occurrence of pulmonary fibrosis in mice. Hericium erinaceus extract can significantly increase the expression of E-cadherin and reduce the mRNA of α-SMA and Vimentin, and show obvious dose dependence, indicating that Hericium erinaceus extract dose-dependently alleviates pulmonary fibrosis in mice. In addition, there was no significant difference in the effects of high-dose Hericium erinaceus extract and nintedanib on the mRNA expression of E-cadherin, α-SMA, and Vimentin, indicating that high-dose Hericium erinaceus extract has a significant effect in alleviating pulmonary fibrosis in mice.

[0055] Example 4: Liquid Chromatographic Analysis and Structural Identification of Hericium erinaceus Extract

[0056] Agilent 1260 liquid chromatograph (purchased from Agilent Technologies (Shanghai) Co., Ltd., Shanghai, China) was used, and the wavelength of the UV detector was 254 nm. The specification of the analytical reverse phase chromatography column was Poroshell 20 Column-C18 (3.0×100 mm. 2.7 μm) (purchased from ANPEL, Shanghai, China). MeOH / v H2O =95 / 5, flow rate =2ml / min. By comparing with the standard, it was determined that the compounds Hericium erinaceus C (RT = 12.84min), Hericium erinaceus D (RT = 16.12min), Hericium erinaceus A (RT = 20.52min), Hericium erinaceus C (RT = 24.56min) existed.

[0057] Example 5: Effects of four components in Hericium erinaceus on abnormal proliferation of primary lung fibroblasts induced by TGFβ

[0058] Mouse primary fibroblasts were extracted and cultured to the logarithmic growth phase, and the density was 5×10 4 The cell suspension of 100 μL / mL was inoculated into a 96-well plate, with 100 μL per well. After culturing for 24 h, 10 ng / mL of TGF-β1 and different concentrations of cypridazole C, cypridazole D, cypridazole A and cypridazole C were added, and the cells were cultured in a cell culture incubator. After 24 h, CCK8 reagent was added, and the absorbance at 450 nm was measured using an ELISA reader. Fig.10 As shown in the results, compared with the blank group, after 24 hours of stimulation with 10 ng / mL TGF-β1, mouse lung fibroblasts proliferated significantly (P<0.001). Compared with the TGF-β1 intervention group, cynomorium oxalis C, cynomorium oxalis D, cynomorium A and cynomorium C significantly inhibited the abnormal proliferation of primary lung fibroblasts induced by TGF-β1 at a concentration of 1-100 μM. In vitro experiments showed that cynomorium oxalis C, cynomorium D, cynomorium A and cynomorium C could significantly inhibit the proliferation of lung fibroblasts, and also suggested that cynomorium oxalis C, cynomorium D, cynomorium A and cynomorium C in Hericium erinaceus extract had certain anti-pulmonary fibrosis effects.

[0059] discuss

[0060] During the process of bleomycin-induced pulmonary fibrosis, as alveolar function was damaged, mice developed respiratory disorders, significantly reduced activity, curled up, decreased fur gloss, reduced food and water intake, and subsequently caused insufficient intake of nutrients in the body and weight loss. The lung organ coefficient is the ratio of the weight of the experimental animal's lung to its body weight, which can approximately reflect the function and pathological changes of the organ. Under normal circumstances, the ratio of each organ to body weight is relatively constant. An increase in the organ coefficient indicates organ congestion, edema or hyperplasia, etc.; a decrease in the organ coefficient indicates organ atrophy and other degenerative changes. The lung organ coefficient is an indicator for evaluating the degree of early pulmonary fibrosis. The experimental results showed that bleomycin-induced acute lung injury caused the mice to lose weight, and the damaged lungs changed significantly. Different doses of drug treatment could change the model lung coefficient (P<0.05). HE and Masson staining results showed that the drug treatment group could improve the ventilation function of the alveoli, especially at high doses, and could inhibit the deposition of fibrous collagen in the process of pulmonary fibrosis. In summary, Hericium erinaceus extract significantly intervened in the process of bleomycin-induced pulmonary fibrosis in mice and had pharmacological effects against pulmonary fibrosis.

[0061] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. Use of a Hericium erinaceus extract in the preparation of a medicine or functional product for treating pulmonary fibrosis.

2. The use according to claim 1, characterized in that The Hericium erinaceus extract is prepared by the following steps: taking Hericium erinaceus fruiting bodies, crushing them, extracting them by heating and refluxing with a 70% ethanol solution, collecting the extract, concentrating it under reduced pressure, and eluting it with 70% ethanol through a macroporous resin column chromatography to obtain the Hericium erinaceus extract.

3. The use according to claim 2, characterized in that The Hericium erinaceus extract mainly contains agamidazole C, agamidazole D, agamidazole A and agamidazole C 4. The use according to claim 1, characterized in that The dosage form of the medicine or functional product is granules, tablets, pills, drops, injections, capsules, powders or decoctions.

Images